Osinusi is vice president, Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead.
Global Study Reports 98.9% SVR with SOF/VEL in Over 7000 Patients With Hepatitis C
May 14th 2025Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.
Read More
Hepatitis D Patients Maintain Undetectable Virus Nearly 2 Years After Bulevirtide Therapy
May 10th 2025Anu Osinusi, MD provides insights on the findings of Gilead’s investigational therapy from its phase 3 MYR301 study, which are being reported at the ongoing European Association for the Study of the Liver (EASL) Congress 2025.
Read More